Skip to content
Search

Latest Stories

Nearly 5 million Britons 'may miss European holidays for taking India-made AstraZeneca vaccine'

Nearly 5 million Britons 'may miss European holidays for taking India-made AstraZeneca vaccine'

AS MANY as five million Britons could remain locked out of their European holidays because the vaccine they took against Covid-19 is not recognised by the European Union’s passport scheme.

Millions of vaccines administered in the UK are yet to qualify for the EU’s vaccine passport scheme since they have been manufactured in India and the European Medicines Agency (EMA) has not yet authorised them, The Telegraph reported.


The situation could see several Britons getting rejected at EU border crossings once the batch numbers on their vaccines are checked digitally. The EU Digital Covid Certificate, which was launched on Thursday (1), is designed to make safe travel across the continent in times of the Covid-19 pandemic. It doesn’t recognise Covishield, the version of the AstraZeneca vaccine produced by the Serum Institute in India (SII) in Pune, Maharashtra, since it has not received approval in Europe yet.

The UK's health department has not revealed how many of the India-made vaccine doses have been administered in the UK, but the UK has seen nearly five million doses of this vaccine having been administered and they are identifiable by vaccine batch numbers (4120Z001, 4120Z002, 4120Z003) that are included on the recipients’ vaccine cards and in the Covid travel pass available via the UK’s NHS app, the report said.

The situation has already sparked an outrage in Asia and Africa where the Covishield, a key part of the COVAX initiative, has been widely used. Now, some British holidaymakers may also find themselves being left out.

‘I feel discriminated against’

The Telegraph contacted three such Britons and none of them had the prior information that they were to receive the Covishield jab. All of them got the Indian version of AstraZeneca in March. “Quite frankly [I feel] discriminated against,” said Hannah Smith, one of them aged 21.

Another individual, who chose not to be identified, said: “That vaccine passports would be a thing is entirely predictable, so our government should have made sure any they purchased would be recognised for travel everywhere.”

The EU Digital Covid Certificate allows those who are either fully vaccinated, recently tested or recovered from Covid-19 to cross borders within the EU without having to serve quarantine or undertake extra coronavirus tests upon arrival. But only vaccines approved by the EMA are included, though individual member states are free to accept other vaccines as well. Nine European countries have given approval for Covishield amid a tussle between India and the EU over ‘green pass’ for Covid vaccines.

The vaccines approved by EMA are Pfizer-BioNTech, Moderna, Johnson & Johnson, and the version of the Oxford-AstraZeneca vaccine made in the UK or Europe, is sold under the brand name Vaxzevria.

Covishield has not sought Europe license

According to The Telegraph report, there is no indication yet that the Indian-manufactured jab is substandard. The EMA has not authorised it only because the Indian makers have not yet sought a license for the product in Europe since the Indian firm manufacturing Covishield aims to predominantly supply to low- and middle-income countries.

Experts though feel that the issue is likely to be resolved if and when the EMA formally authorises Covishield jab in Europe.

Earlier this week, SII's chief executive officer Adar Poonawalla said on Wednesday (30) they were confident of getting approval from the EMA for Covishield. According to him, the issue of vaccine passports should be on the basis of reciprocity between countries.

“The EMA is absolutely correct in asking us to apply, which we have through AstraZeneca, our partners, a month ago, and that process has to take its time. An approval process even with UK MHRA, WHO took its time and we have applied to the EMA,” Poonawalla, who moved to London in May after allegedly facing threatening calls from powerful people in India, said at India Global Forum 2021.

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Serena Williams

Williams explained that her weight challenges began after the birth of her first daughter

Getty Images

Serena Williams says GLP-1 made her feel light physically and mentally after 31lb loss

Highlights:

  • Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
  • The tennis legend says the treatment enhanced her existing healthy lifestyle
  • She stresses that weight loss should not change self-image or self-confidence

Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.

The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.

Keep ReadingShow less